Clinical Research Directory

Inclusion Criteria: * Age 18 years or older * ECOG performance status (PS) 0-2 * Expected survival of at least 12 weeks * CD20-positive marginal zone lymphoma confirmed according to WHO 2022 lymphoma classification standards, including the three subtypes: nodal MZL, extranodal MZL, and splenic MZL * Measurable lesions by contrast-enhanced computed tomography/magnetic resonance imaging (CT/MRI) * Meet the NCCN guideline criteria for MZL treatment and have not previously received systemic therapy for MZL (excluding hormone therapy and anti-infective treatment) * Main organ function within normal limits, meeting the following criteria (excluding abnormalities caused by lymphoma): 1. Hematology test standards: 1. ANC ≥ 1.0 × 10\^9/L 2. PLT ≥ 75 × 10\^9/L (for patients with confirmed bone marrow involvement: ≥ 50 × 10\^9/L) 3. Hb ≥ 80 g/L 2. Biochemistry test standards: 1. TBIL \< 2 × ULN 2. ALT and AST \< 2.5 × ULN (for patients with liver involvement, ALT and AST \< 5 × ULN) 3. Endogenous creatinine clearance ≥ 40 ml/min (Cockcroft-Gault formula) * Women of childbearing potential must use reliable contraception or have a negative pregnancy test (blood or urine) within 7 days prior to enrollment and agree to use appropriate contraception during the trial and for 8 weeks after the last dose of the study drug. For men, agreement to use appropriate contraception during the trial and for 8 weeks after the last dose of the study drug or previous surgical sterilization is required * Subjects voluntarily agree to participate in this study, sign the informed consent form, have good compliance, and cooperate with follow-up Exclusion Criteria: * Patients with central nervous system involvement * Patients with a history of or concurrent untreated malignant tumors, except for cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer * Patients with the following cardiovascular diseases: myocardial ischemia or myocardial infarction of grade II or above, uncontrolled arrhythmias (including QTc interval ≥450 ms for men, ≥470 ms for women); heart failure of NYHA class III-IV, or left ventricular ejection fraction (LVEF) \<50% as indicated by cardiac ultrasonography; 4. Coagulation dysfunction (INR \>1.5 or prothrombin time (PT) \> ULN + 4 seconds, or APTT \>1.5 ULN), bleeding tendency, or currently receiving thrombolytic or anticoagulant therapy * Arterial or venous thrombotic events occurring within 12 months prior to enrollment, such as cerebrovascular events (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, or pulmonary embolism * Known genetic or acquired bleeding or thrombotic disorders (e.g., hemophilia, coagulation disorders) * Major surgery or severe traumatic injury, fracture, or ulceration within 4 weeks prior to enrollment * Factors significantly affecting oral drug absorption, such as dysphagia, chronic diarrhea, or intestinal obstruction * Active infections requiring antimicrobial treatment (e.g., antibacterial or antiviral drugs, excluding chronic hepatitis B antiviral therapy or antifungal treatments); 10. Active hepatitis B (HBV DNA ≥2000 IU/mL or 104 copies/mL) or hepatitis C (HCV antibody positive and HCV RNA above the detection limit of the assay) * History of substance abuse of psychiatric drugs that cannot be discontinued or mental disorders * Participation in another anti-tumor drug clinical trial within 4 weeks prior to enrollment * Treatment with strong CYP3A4 inhibitors within 7 days prior to enrollment, or treatment with strong CYP3A4 inducers within 12 days prior to enrollment * Pregnant or breastfeeding women; patients of childbearing potential who are unwilling or unable to use effective contraception * Other conditions that the investigator deems may affect the conduction of the clinical study or the assessment of study results